关于杜皮森特®和伊特佩基马布治疗COPD和喘的20篇摘要将在2024年ERS大会上发表. 20 abstracts on Dupixent® and Itepekimab for COPD and asthma treatment to be presented at ERS Congress 2024.

关于Dupixent(杜皮鲁马)和调查疗法Itepekimab的20份摘要将在欧洲遥感学会2024年大会上介绍,展示治疗呼吸道疾病(如肺炎和哮喘)的潜力。 20 abstracts on Dupixent® (dupilumab) and investigational therapy Itepekimab will be presented at ERS Congress 2024, showcasing potential for treating respiratory diseases like COPD and asthma. 瑞格内龙和赛诺菲将介绍杜皮森特在慢性肺炎中减轻恶化和改善肺功能的数据. Regeneron and Sanofi will present data on Dupixent's exacerbation reduction and lung function improvement in COPD. 其他报告包括新的喘成像研究和前吸烟者患有COPD的Itepekimab数据,强调针对关键炎症驱动因素以改善患者的治疗结果. Other presentations include novel asthma imaging studies and Itepekimab data in former smokers with COPD, highlighting targeting key inflammation drivers to improve patient outcomes.